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Summary
Pseudohypoparathyroidism (PHP) is a group of disorders de-
fined by the presence of renal parathyroid hormone (PTH) resis-
tance, resulting in biochemical hypoparathyroidism in the pres-
ence of elevated serum PTH levels. Most PHP patients have di-
minished urinary cyclic AMP responses to administered PTH,
indicating a defect in proximal PTH signaling. Heterozygous in-
activating mutations of Gs , the G protein which couples hor-
mone and other receptors to intracellular cyclic AMP produc-
tion, lead to Albright hereditary osteodystrophy (AHO), a disor-
der characterized by skeletal defects, short stature, obesity,
and neurobehavioral defects. Maternal inheritance of Gs m u t a-
tions leads to both AHO and resistance to multiple hormones,
including PTH, a condition referred to as PHP type 1a. In con-
trast, paternal inheritance of the same mutations leads to AHO
alone. This is because Gs is imprinted in a tissue-specific
manner, and is poorly expressed from the paternal allele in vari-
ous tissues, including renal proximal tubules. PHP type 1b pa-
tients have renal PTH resistance in the absence of AHO result-
ing from imprinting defects of the Gs gene (G N A S) in which
both parental alleles have a paternal-specific imprinting pattern.
The maternal imprint is lost in one specific region located just
upstream of the Gs promoter, which likely leads to Gs d e f i-
ciency in specific tissues (such as proximal tubules) where Gs
is normally expressed primarily from the maternal allele. Famil-
ial PHP type 1b is also associated with a deletion mutation up-
stream of G N A S within a region presumed to be important for
G N A S imprinting. This mutation only leads to a G N A S i m p r i n t-
ing defect and PTH resistance when it is inherited maternally.
KEY WORDS: pseudohypoparathyroidism, genomic imprinting, G protein,
cyclic AMP.
Introduction
Pseudohypoparathyroidism (PHP) is a group of disorders in
which patients develop the signs and symptoms of hy-
poparathyroidism due to end organ resistance to parathyroid
hormone (PTH) (1, 2). Patients with this disorder always pre-
sent with elevated levels of serum PTH, which is usually, al-
though not always, associated with hypocalcemia and hyper-
phosphatemia. PTH resistance in PHP is primarily manifested
in the renal proximal tubule. Because this tissue is unable to
respond to PTH, patients have reduced renal phosphate clear-
ance, leading to hyperphosphatemia. The combined effects of
hyperphosphatemia and reduced PTH responsiveness leads to
reduced synthesis of 1,25 dihydroxyvitamin D (1,25D) in proxi-
mal tubules. 1,25D deficiency leads to hypocalcemia through
reduced gastrointestinal calcium absorption and PTH-stimulat-
ed calcium release in bone. 
The PTH resistance in PHP appears to be limited to renal prox-
imal tubules. Osteoblastic cells isolated from PHP patients
have normal PTH responsiveness (3, 4) and some PHP pa-
tients present with hyperparathyroid bone disease due to the
skeletal effects of chronically elevated PTH levels (5, 6). PTH
action in the distal nephron (which promotes calcium reabsorp-
tion) also remains intact, and this is why PHP patients, unlike
patients with primary hypoparathyroidism, are not prone to hy-
percalciuria upon treatment (7). 
PTH mediates its actions by binding to a seven transmem-
brane receptor that can bind PTH and PTH related peptide
(PTHrP) with similar affinities (8, 9). Upon hormone binding,
this receptor activates two heterotrimeric G proteins. At lower
hormone concentrations the G protein Gs is activated, leading
to stimulation of adenylyl cyclase and generation of the second
messenger cyclic AMP (cAMP). cAMP mediates most of its ac-
tions by interacting with the cAMP-dependent protein kinase
(protein kinase A), although other cAMP effectors have been
more recently identified (10). cAMP mimics the effects of PTH
on renal phosphate handling and vitamin D metabolism (11). At
higher hormone concentrations the PTH/PTHrP receptor is al-
so able to activate the G protein Gq, which stimulates phospho-
lipase C.
Most PHP patients (PHP type 1) have a markedly reduced uri-
nary cAMP response to administered PTH (12, 13), indicating
the presence of a signaling defect involving the receptor, Gs, or
adenylyl cyclase in renal proximal tubule cells. Rarely patients
will have a normal cAMP response but a reduced phosphaturic
response to PTH (PHP type 2), consistent with a defect down-
stream of cAMP generation (14). However the defect in PTH
responsiveness in PHP type 2 patients is usually reversed after
treatment with calcium or vitamin D, indicating that this is not a
fixed genetic defect but rather a secondary and reversible ef-
fect of hypocalcemia and/or vitamin D deficiency (15). 
In most cases PHP type 1 results from reduced Gs activity due
to genetic or epigenetic defects of the gene encoding it’s specif-
ic a-subunit Gsa. Like all heterotrimeric G proteins, Gs is com-
posed of three subunits (a, b, and g) which are all the products
of separate genes (16). Gsa interacts with both receptors and
effectors, such as adenylyl cyclase, and has a guanine nu-
cleotide binding site. The b and g subunits form tightly bound
heterodimers. In the inactive state Gsa has GDP bound to the
guanine nucleotide binding site and is associated with bg. T e
hormone bound receptor promotes GDP release, which leads to
GTP binding and dissociation of Gsa from b g. The active GTP-
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bound Gsa is capable of interacting with and stimulating adeny-
lyl cyclase. Gsa is inactivated by an intrinsic GTPase activity
that hydrolyzes bound GTP to GDP. Mutations within specific
residues (Arg2 0 1, Gln2 2 7) critical for the GTPase reaction lead to
constitutively active forms of Gsa , and such somatic mutations
are the genetic cause of various endocrine tumors, fibrous dys-
plasia of bone, and the McCune-Albright syndrome (2, 17-19).
Recent studies suggest that Gsa may have other effectors be-
sides adenylyl cyclase, such as s r c tyrosine kinase (20).
The gene encoding Gs a is named G N A S and is located at
20q13 (21). The Gsa coding region is spread over 13 exons. Al-
ternative splicing of exon 3 results in the generation of long and
short forms of Gsa protein that are all capable of mediating sig-
naling between receptor and adenylyl cyclase. G N A S is now rec-
ognized to be a complex imprinted gene which generates multi-
ple gene products through the use of alternative promoters and
first exons which splice onto a common set of downstream ex-
ons (exons 2-13, see Fig. 1) (16). The most upstream promoter
generates transcripts for the chromogranin-like protein NESP55,
which is structurally and functionally unrelated to Gsa . The next
promoter generates transcripts for XLa s, a neuroendocrine-spe-
cific Gsa isoform that has an extra-long amino-terminal extension
encoded within its specific first exon. NESP55 and XLa s are op-
positely imprinted: NESP55 is expressed only from the maternal
allele and its promoter region is DNA methylated on the paternal
allele while XLa s is only expressed from the paternal allele and
its promoter is methylated on the maternal allele (22, 23). The
X La s promoter region also generates paternal-specific antisense
transcripts that are likely to be important for paternal NESP55
imprinting (24). The next promoter region (the exon 1A region),
which is located 35 kilobases downstream of the XLa s promoter
is methylated on the maternal allele and generates untranslated
transcripts of unknown function from the paternal allele (25, 26).
Just downstream of exon 1A is the Gsa promoter, which is un-
methylated even though, as discussed below, Gsa is imprinted in
a tissue-specific manner (26).
PHP type 1 can be further subcategorized (Table I) based up-
on the type of underlying Gsa defect and the presence or ab-
sence of Albright hereditary osteodystrophy (AHO), a congeni-
tal syndrome characterized by skeletal defects, short stature,
and obesity. PHP type 1a is defined as the co-occurrence of
renal PTH (and other hormone) resistance and AHO and is
caused by heterozygous inactivating Gsa mutations. PHP type
1b patients have renal PTH resistance in the absence of AHO,
which results from a G N A S imprinting defect. Rarely patients
with the PHP type 1a phenotype have no evidence for a Gsa
defect, and this has been referred to as PHP type 1c. In this re-
view we will focus on the genetic and epigenetic defects asso-
ciated with PHP types 1a and 1b, respectively.
Pseudohypoparathyroidism type 1a (Albright hereditary
osteodystrophy)
AHO is a congenital syndrome in which patients present with
short stature, brachydactyly, obesity, subcutaneous ossifica-
tions, facial features such as hypertelorism or depressed nasal
bridge, and mental deficits or developmental delay (Fig. 2). The
severity of the phenotype varies significantly, and 50% or less
present with neurobehavioral problems (27, 28). Even within
he same kindred, some affected patients also develop resis-
tance to PTH, thyrotropin and gonadotropins (PHP type 1a)
while other affected patients develop AHO but have no evi-
dence for hormone resistance (a condition also known as
pseudopseudohypoparathyroidism [PPHP]). 
All AHO patients (both PHP type 1a and PPHP patients) have
a ~50% reduction in Gs bioactivity in membranes from various
tissues, such as blood cells and fibroblasts (29, 30), and this is
ue in most cases to a similar reduction in Gsa mRNA and/or
protein expression (31-33). As these findings would predict,
most AHO (both PHP type 1a and PPHP) patients have het-
erozygous inactivating mutations within or surrounding the Gsa
coding region exons (34-36). These mutations are spread
throughout the Gsa coding exons and splice junctions, with the
exception of exon 3, probably because transcripts with this ex-
on spliced out still produce a functional Gsa protein. There is
no obvious differences in phenotype between patients with ex-
on 1 mutations (which only affect Gsa expression) from muta-
tions in the other downstream exons which are common to all
transcripts, suggesting that the phenotype results specifically
from Gsa deficiency. One 4 base pair deletion in exon 7 has
been identified in >22 families, which probably results from
pausing of DNA polymerase and slipped-strand mispairing dur-
ing replication (37). Several other mutations have also been re-
ported in more than one kindred, but most mutations have
been identified in one kindred each.
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Figure 1 - General organization of the GNAS locus. The maternal (Mat,
above) and paternal (Pat, below) alleles of GNAS are depicted with re-
gions of methylation shown above (METH) and splicing patterns shown
below. Transcriptionally active promoters are indicated by horizontal ar-
rows in the direction of transcription. The alternative first exons for NE-
SP55 (NESP), XLa s, paternal untranslated mRNA transcripts (exon
1A), and Gsa (exon 1) are shown splicing onto a common downstream
exon (exon 2). The first exon for paternal antisense transcripts are also
shown (NESPAS). Common downstream exons 3-13 as well as the
downstream exons of the antisense transcript (NESPAS) are not
shown. Gsa is paternally imprinted in some tissues, indicated by the
dashed arrow. The diagram is not drawn to scale.
Figure 2 - Features of AHO. A. Photograph of AHO patient showing
obesity, rounded face, and short stature. B. Hand radiograph showing
brachydactyly of the 4th metacarpal bone.
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Most inactivating mutations are frameshift or splice junction
mutations that prevent mRNA expression or missense muta-
tions which lead to unstable proteins and reduced protein ex-
pression. With few exceptions there is no obvious genotype-
phenotype correlation. However some missense mutations
lead to specific defects in Gsa biochemical function. Various
mutations altering carboxy-terminal residues prevent G protein
receptor interactions (38, 39). Mutations in Glu2 5 9 or Arg2 3 1
within the conformational switch regions lead to a receptor acti-
vation defect due to an inability to stabilize the active confor-
mation (40, 41). A mutation at residue Arg258 leads to both in-
creased GDP binding in the basal state and an increased rate
of GTP hydrolysis in the active state (42, 43). The Ala366 to ser-
ine mutation leads to an interesting phenotype in which males
develop the co-occurrence of PHP type 1a and gonadotropin-
independent precocious puberty (44). This mutation promotes
GDP release in the absence of hormone receptor stimulation.
At core body temperature the resulting protein is thermolabile
due to the lack of bound guanine nucleotide, resulting in PHP
type 1a. At the slightly lower temperature of the testis, the pro-
tein is stable but is constitutively activated as GDP release is
the rate-limiting step for G protein activation.
The fact that identical Gsa mutations are present in both PHP
type 1a and PPHP patients within the same kindred confirms
that AHO is an autosomal dominant disorder that probably is
the result of Gsa haploinsufficiency in most tissues. However
this could not explain how a heterozygous mutation could re-
sult in multihormone resistance in only a subset of patients.
The first clue to this paradox was the observation that whether
or not an individual develops hormone resistance (PHP type
1a) is dependent on parental inheritance: maternal inheritance
results in PHP type 1a in offspring while paternal inheritance
results in PPHP (45). Studies in a Gsa knockout model showed
that this inheritance pattern is explained by genomic imprinting
of Gsa (46) (Fig. 3). Gsa is primarily expressed from the mater-
nal allele in proximal tubules, and therefore mutation of the ac-
tive maternal allele leads to Gsa deficiency in this tissue and
renal PTH resistance. In contrast, paternal mutations have little
or no effect on Gsa expression in proximal tubules or PTH ac-
tion. Studies have now confirmed that Gsa is also imprinted in
human pituitary, thyroid, and ovary (47-50) and this likely ex-
plains why PHP type 1a patients often present with growth hor-
mone deficiency (51, 52), thyrotropin resistance and hypothy-
roidism (53, 54), and ovarian dysfunction (55). 
However Gsa imprinting is tissue-specific and therefore Gsa is
biallelic expressed in most tissues, including the renal medulla
and most likely bone. This is consistent with the fact that both
maternal and paternal heterozygous Gsa mutations (in PHP
type 1a and PPHP, respectively) produce Gsa haploinsufficien-
cy in most tissues, and this haploinsufficiency is most likely the
underlying cause of the AHO syndrome. Tissue-specific Gsa
imprinting is also the likely explanation for why PHP type 1a
patients do not have skeletal PTH resistance (3) and do not
lose the ability of PTH to stimulate calcium reabsorption in the
distal nephron (7). Likewise it can explain why PHP type 1a pa-
tients do not show clinical resistance to other hormones also
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Figure 3 - Tissue-specific Gsa imprinting and the effect of heterozygous
null mutations. In renal proximal tubules (above) Gsa is imprinted on
the paternal allele (denoted with X). Mutation (Mut) on the active mater-
nal allele (gray rectangle, left panel) leads to almost total Gsa deficien-
cy and PTH resistance while mutation on the paternal allele (right pan-
el) has little effect on Gsa expression or PTH sensitivity. This is con-
firmed by immunoblots of renal cortical membranes isolated from wild
type mice (WT) and mice with disruption of the GNAS maternal (m-/+)
and paternal (+/p-) alleles, respectively (46). In most other tissues (be-
low) Gsa is not imprinted and therefore both maternal and paternal mu-
tations lead to ~50% loss of Gsa expression, as shown in immunoblots
of renal inner medulla membranes from the same mice (46). (Figure
adapted from Weinstein, et al. Endocr Rev. 2001; 22:675-705).
Table I - Different forms of pseudohypoparathyroidism (PHP).
Accompanying Features Gene Defect
PHP type 1a AHO, multihormone resistance Maternal Gsa null mutations
PHP type 1b Borderline TSH resistance in some cases GNAS imprinting defect with maternal STX16 deletion (familial)
GNAS imprinting defect (sporadic)
Paternal uniparental disomy of 20q
Maternal deletion of Gsa isoleucine 382
PHP type 1c AHO, multihormone resistance No Gsa defect; Defect unknown
PHP type 2 Often calcium, vitamin D deficiency None known; probable secondary physiological defect
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known to work through Gs a (e.g. adrenocorticotropin, vaso-
pressin), as Gsa is not imprinted in their respective target tis-
sues. 
Because of the non-specific nature of many of the features of
AHO and the presence of other genetic defects that can mimic
AHO [e.g. acrodysostosis (56), AHO-like syndrome mapped to
distal chromosome 2 (57)], the diagnosis of AHO should not be
made in the absence of a clear family history of PHP type 1a,
multihormone resistance, or documented genetic or biochemi-
cal Gsa defect. While typically AHO is associated with relatively
benign subcutaneous ossifications, a few patients with het-
erozygous Gsa mutations develop large plate-like ossifications
that invade into deeper tissues such as muscle and cause se-
vere deformity and reduced mobility (referred to as progressive
osseous heteroplasia) (58). The mutations in these patients are
often identical to those found in more typical AHO patients, so
it does not appear that this more severe form of ectopic ossifi-
cation results from more severe Gsa mutations. 
Pseudohypoparathyroidism type 1b
PHP type 1b patients have renal PTH resistance that is similar
to that in PHP type 1a patients, but lack the features of the
AHO phenotype. As in PHP type 1a, the urinary cAMP re-
sponse to administered PTH is markedly reduced in these pa-
tients, indicating a proximal signaling defect (53). Several lines
of evidence have ruled out PTH/PTHrP receptor defects as the
cause of PHP type 1b (59, 60). In contrast to PHP type 1a,
PHP type 1b is associated with normal Gsa expression and
bioactivity in erythrocyte membranes (53, 61), ruling out typical
loss-of-function mutations within or surrounding the Gsa coding
exons as the underlying defect. Lack of Gsa haploinsufficiency
may likely explain why these patients do not develop AHO. 
While in most cases PHP type 1b is an apparently sporadic dis-
ease, in some instances the disease occurs in a familial manner.
The first evidence that PHP type 1b is due to a G N A S d e f e c t
came from a study showing that familial PHP type 1b genetically
mapped to 20q13 in the vicinity of the G N A S gene (62). More-
over in the families that were studied PTH resistance only oc-
curred when an individual inherited the trait from his or her moth-
er, similar to the inheritance pattern of PTH resistance present in
AHO/PHP type 1a. Subsequently it has been shown that virtually
all cases of PHP type 1b (both familial and sporadic) are associ-
ated with a G N A S imprinting defect in which both parental alleles
have a paternal imprinting pattern, or epigenotype (25, 63, 64).
In proximal tubules, where Gsa is normally expressed primarily
from the maternal allele, the presence of a paternal epigenotype
on both parental alleles should lead to Gsa deficiency and PTH
resistance. In most other tissues where Gsa is normally ex-
pressed equally from both parental alleles, the imprinting defect
should have no effect on Gsa e x p r e s s i o n .
In most cases familial PHP type 1b is associated with both a 3
kilobase deletion within the linked S T X 1 6 gene located up-
stream of G N A S and loss of maternal-specific imprinting
(methylation) of the exon 1A differentially methylated region
(DMR) (65) (L.S.W., J.L., unpublished results). Presumably the
deleted region contains one or more c i s -acting elements that
are critical for establishing the methylation of the exon 1A DMR
during oogenesis, but that are not important for establishing the
imprinting of the intervening NESP55 and XLa s regions. When
the deletion is inherited from the mother it appears to result in
loss of maternal-specific exon 1A DMR methylation and PTH
resistance. When the deletion is inherited from the father it has
no effect on exon 1A DMR methylation (as the paternal allele is
normally unmethylated) or on PTH action. Sporadic cases of
PHP type 1b are not associated with the STX16 deletion muta-
tion but are associated with GNAS imprinting defects (25, 65)
(L.S.W., J.L., unpublished results). Some patients have imprint-
ing defects involving only the exon 1A DMR while most have
more global GNAS imprinting defects which involve either the
whole locus or the exon 1A, NESP55, and XLa s/antisense pro-
oters, but not XLa s exon 1 (25) (L.S.W., J.L., unpublished re-
sults). In one patient PTH resistance was associated with pa-
ternal uniparental disomy of the long arm of chromosome 20
(66). It is unclear whether the imprinting defects in sporadic
PHP type 1b result from underlying genetic mutations or are
the result of a failure in the imprinting mechanism that may
rarely occur in a random manner.
In both familial and sporadic PHP type 1b, the loss of maternal-
specific exon 1A DMR methylation is the epigenetic defect that
is consistently associated with renal PTH resistance. We have
proposed a model in which the exon 1A DMR has a cis-acting
regulatory element (silencer or insulator) for the Gsa promoter
that is both methylation-sensitive and tissue-specific (16, 25).
In the example shown in Fig. 4 a silencer within the exon 1A
DMR binds a tissue-specific repressor on the paternal allele in
proximal tubules, which suppresses Gs a expression from the
paternal allele. The repressor fails to bind to the maternal allele
because the silencer is methylated, allowing the Gsa promoter
to remain active in the maternal allele. In most other tissues the
repressor is not expressed, and therefore Gsa is biallelically
expressed. In PHP type 1b the exon 1A methylation on the ma-
ternal allele is absent. This allows the repressor to bind to both
alleles in proximal tubules, leading to Gsa deficiency and renal
PTH resistance. In most other tissues Gsa expression is unaf-
fected because the repressor is absent. This model is support-
ed by results in mice with deletion of the exon 1A DMR
(L.S.W., J.L., unpublished results). Paternal deletion of the ex-
on 1A DMR resulted in Gsa overexpression in renal proximal
tubules and lower levels of circulating PTH (consistent with
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Figure 4 - Proposed model for tissue-specific Gsa imprinting and patho-
genesis of PHP type 1b. In each panel the maternal (Mat) and paternal
(Pat) alleles are depicted with a cis-acting silencer element (S) within
the exon 1A differentially methylated region and Gsa exon 1 (1). In nor-
mal subjects (upper panels) the region containing the silencer is methy-
lated (Meth) on the maternal allele. In proximal tubules (left hand panel)
a tissue-specific repressor protein (R) binds to the silencer on the pater-
nal allele and suppresses expression from the Gsa promoter on this al-
lele. Methylation of the silencer on the maternal allele prevents binding
of the repressor, allowing the maternal Gsa promoter to remain active.
In most other tissues (right hand panel) the repressor is absent and
therefore Gsa is biallelically expressed. In PHP type 1b (lower panels)
methylation is absent, allowing the repressor to bind to both alleles in
proximal tubules, resulting in Gsa deficiency. Methylation has no effect
on Gsa expression in other tissues because the repressor is absent. 
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higher PTH sensitivity), presumably due to the absence of the
cis-acting negative regulatory element on the paternal allele. In
contrast, the maternal deletion had no effect.
One family has been reported in which PHP type 1b resulted
from a inherited Gsa missense mutation (deletion of isoleucine
382) within the carboxyl terminal region of Gsa (39). Biochemi-
cal analysis of the mutant protein showed it to be unable to be
activated by the PTH/PTHrP receptor, although it could be acti-
vated by other Gsa receptors. Because of this selective recep-
tor coupling defect the affected patients developed PTH resis-
tance without developing AHO or other hormonal defects. Con-
sistent with the paternal imprinting of Gsa , the mutation only re-
sulted in PTH resistance when it was inherited maternally. 
Because Gsa is also partially imprinted in thyroid cells (48-50),
one might expect that PHP type 1b patients may also have evi-
dence for TSH resistance. Although it was originally reported
that TSH resistance is not a feature of PHP type 1b, it has
been more recently shown that almost 50% of PHP type 1b pa-
tients confirmed to have the exon 1A methylation defect have
evidence for borderline or mild TSH resistance as well (50, 66).
Conclusions
PHP is a genetically heterogeneous group of disorders which is
defined by the presence of renal PTH resistance. Because Gsa
is normally expressed primarily from the maternal allele in renal
proximal tubules, Gsa deficiency and PTH resistance may re-
sult from either loss-of function genetic mutations (PHP type
1a) or epigenetic changes (PHP type 1b) in the GNAS mater-
nal allele which lead to loss of Gsa expression or expression of
a bioinactive protein. Mutations on the maternal allele in PHP
type 1a also lead to mild to moderate hormone resistance in
other organs where Gsa is imprinted. In addition these muta-
tions lead to Gs a haploinsufficiency in most other tissues
where Gsa is normally not imprinted, and this probably is the
underlying cause of the AHO phenotype. Patients who inherit
these mutations paternally only develop the AHO phenotype.
Familial PHP type 1b is usually associated with a deletion mu-
tation in a closely linked gene that presumably leads to a spe-
cific GNAS imprinting defect by unknown mechanisms. Almost
all PHP type 1b patients have lost the maternal-specific im-
printing of the exon 1A DMR located just upstream of the Gsa
promoter region, and this epigenetic change presumably leads
to Gsa deficiency in tissues, such as proximal tubules, where
Gsa is normally expressed primarily from the maternal allele. 
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